# Cloning and Expression of Mouse UDP-GalNAc:Polypeptide N-Acetylgalactosaminyltransferase-T3

Jane Zara, Fred K. Hagen, Kelly G. Ten Hagen, Brian C. Van Wuyckhuyse, and Lawrence A. Tabak<sup>1</sup>

Departments of Dental Research and Biochemistry, School of Medicine and Dentistry, University of Rochester, 601 Elmwood Avenue, Rochester, New York 14642

Received September 24, 1996

A novel isoform of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase, designated ppGaN-Tase-T3, has been cloned from a mouse testis cDNA library and expressed in COS7 cells. ppGaNTase-T3 displayed 64 and 59% amino acid identity with ppGaNTase-T1 and ppGaNTase-T2, respectively, and 96% amino acid identity with the recently reported human form of ppGaNTase-T3. The ppGaNTase-T3 transcript is abundant in the major salivary glands, gastrointestinal tract and both the male and female reproductive systems. ppGaNTase-T3 and ppGaNTase-T1 display overlapping substrate preferences in vitro, although mapping studies of O-glycosylated peptides suggests that certain hydroxyamino acids are preferentially glycosylated by each isoform. This suggests that more than one isoform of ppGaNTase may be required to complete the O-glycosylation of endogenous substrates. © 1996 Academic Press, Inc.

UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase (EC 2.4.1.41) is the enzyme which catalyzes the reaction UDP-GalNAc + polypeptide-(Ser/Thr)-OH  $\rightarrow$  GalNAc  $\alpha$ -O-Ser/Thr-polypeptide + UDP, thereby initiating O-glycosylation of serine and threonine residues on an array of glycoproteins (1, 2). Recent studies have demonstrated that there are multiple ppGaNTases and that these isoforms vary in both their pattern of expression and in vitro substrate specificity (1-5).

A human expressed sequence tag (hEST, T11328) was reported which displayed regions of sequence similarity which are common among divergent species of the ppGaNTase, suggesting that the hEST encoded a novel isoform of ppGalNAc (3). While this work was in progress, a human salivary gland cDNA corresponding to this hEST was isolated, expressed and shown to encode a novel form of the transferase, termed ppGaNTase-T3 (5). In this report, we have cloned, sequenced and expressed the mouse cDNA corresponding to this hEST, and demonstrate that recombinant mouse ppGaNTase-T3 preferentially glycosylates certain hydroxyamino acids in multi-site substrates, in vitro.

## MATERIALS AND METHODS

Northern blot analysis. Following electrophoresis, mouse RNA samples (6) were transferred to Hybond-N membranes (Amersham). A probe consisting of nt1-822 of hEST-T11328 (3) was used to detect transcript. The anti-sense strand of this fragment was labeled by asymmetric PCR using the 3' antisense oligonucleotide 5'ACGAGACCTTGA-GCAGCAT3', (Universal DNA, Inc.) as described previously (7). Antisense 18S ribosomal subunit oligonucleotide 18S anti-5'TATTGGAGCTGGAATTACCGCGGCTGCTGG3' was end-labeled as described (6) and used to normalize loading of samples. All hybridizations were performed in 5× SSPE/50% formamide at 42°C with two final washes in 2× SSC/0.1% SDS at 65°C for 20 min.

Cloning and sequencing the mouse homologue of hEST T11328. A mouse testis cDNA library (Unizap XR;

<sup>&</sup>lt;sup>1</sup> To whom correspondence should be addressed.

Abbreviations: ppGaNTase: UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase; UDP-GalNAc: uridine diphospho-N-acetyl-D-galactosamine (EC 2.4.1.41); PTH: phenylthiohydantoin.

 $\begin{tabular}{ll} TABLE & 1 \\ Summary of Substrates Glycosylated in Vitro with ppGaNTase-T3 and -T1 \\ \end{tabular}$ 

D4: 4-				<u>T3</u>	<u>T1</u>
Peptide Name	Sequence	Derived from	Reference	fmoles Gal	INAc/µg/min <sup>a</sup>
EA2	PTTDSTTPAPTTK	Rat submandibular mucin	(9)	172 ± 19	3598 ± 97
Muc 1a	APPAHGVTSAPDTRPAPGC	Muc 1 mucin type glycoprotein	(7)	$113 \pm 5$	$1670 \pm 529$
Muc 1b	PDTRPAPGSTAPPAC	Muc 1 mucin type glycoprotein	(7)	$29 \pm 1$	$125 \pm 3$
Muc 2	PTTTPISTTTMVTPTPTPTC	Human intestinal mucin	(8)	$310 \pm 9$	$2969 \pm 187$
AWN1a	AIPPLNLSCGKE	Porcine spermadhesin AWN-1	(10)	_	_
MCP1	LPPSSTKPPALSHS	Membrane cofactor protein	(11)	$59 \pm 3$	$339 \pm 34$
MCP2	STSSSTTKSPASSAS	Membrane cofactor protein	(11)	$157 \pm 14$	$1061 \pm 142$
MCP3	GPRPTYKPPVSNYP	Membrane cofactor protein	(11)	25 ± 2	257 ± 19

<sup>&</sup>lt;sup>a</sup> Transfections for each construct were performed simultaneously and enzyme assays performed in triplicate.

Stratagene) was screened ( $1 \times 10^6$  plaques) using the manufacturer's protocol and the hEST probe described above. Bi-directional sequencing was performed by a combination of fluorescence (Ladderman enzyme, Pan Vera; with a Model 4000L LiCor Automated DNA Sequencer) and radioactive methods (Taq-Trac; Perkin Elmer).

Subcloning the mouse homologue of hEST T32595. An amino truncated form of the putative glycosyltransferase, lacking the first 49 amino acids, was generated by PCR using primers 5'CACACGCGTCAAAGATGGAGAGGAACTTGAAAA and 5'CACGGATCCGTATTCTAGTTGCTGTGCTTTC to obtain a secreted form of the enzyme from COS7 cells. Amplification was performed at 95°C, 5 min; 53°C, 1.5 min; and 72°C, 3 min for 20 cycles, and the product inserted into pSVL (Pharmacia) containing an insulin secretion signal adjacent to the amino terminus of truncated mouse cDNA by utilizing engineered BamHI and MluI sites (2).

Cell culture and transient transfections. COS7 cells were maintained in DMEM (Gibco/BRL) 10% fetal calf serum in 5% CO<sub>2</sub> at  $37^{\circ}$ C. Cells were transiently transfected using DEAE dextran (6). Twelve to 18 h after, transfection cells were grown at  $30^{\circ}$ C and harvested 3d post-transfection. Secreted recombinant protein was harvested from cell supernatants (2). Sham transfections were performed with pSVL lacking transferase insert.

*In vitro glycosylation assays.* ppGaNTase assays were performed as described previously (2) using COS7 cell culture supernatant as the source of recombinant enzyme. For comparison, recombinant mouse ppGaNTase-T1 (F.K. Hagen and L.A. Tabak, unpublished) was expressed and assayed in an identical fashion.

A panel of synthetic peptide substrates, synthesized by FMOC chemistry using a Milligene 9050 synthesizer, were used to assay for ppGaNTase activity (Table 1). The integrity of each peptide was confirmed by Edman degradation and mass spectroscopy; peptide concentrations were verified by amino acid analysis of acid hydrolyzed sample. Substrate glycosylation was compared by incubating 400  $\mu$ M of each peptide substrate (Table I), 50  $\mu$ M  $^{14}$ C-UDP-GalNAc (16.4 mCi/mmole). Reactions were stopped by addition of 30 mM EDTA. Glycosylated products were resolved from unincorporated  $^{14}$ C-UDP-GalNAc with anion-exchange (BioRad AG 1X-8) spin columns after verifying results by direct measurement of peptide isolated by reverse phase HPLC (12). Protein concentrations of culture supernatants were determined by the method of Lowry (13).

Peptide mapping. Recombinant enzyme (8  $\mu$ l of transfected culture supernatant [2.7 or 4.4 mg/ml for ppGaNTase-T1 and T3, respectively]) was added to 2 mM UDP-GalNAc and 200  $\mu$ M of either EA2 or MCP-2 (in 100  $\mu$ l). Following incubation (6-8h at 37°C), an additional 4  $\mu$ l of recombinant enzyme was added and then incubated (8-10h at 37°C). Resultant products were covalently coupled to polyvinylidene difluoride membranes (Sequelon; Millipore). Edman degradation was performed with modified cycles for trifluoroacetic acid cleavage and extractions. Glycosylated effluents from each cleavage cycle were counted for <sup>14</sup>C-GalNAc incorporation and nonglycosylated residues were converted to PTH amino acids and quantitated as described previously (12).

## RESULTS AND DISCUSSION

Given the abundance of ppGaNTase transcript in testis as determined by a preliminary northern blot analysis, we screened a mouse testis cDNA library. Of the eighteen positive clones isolated, one contained the entire open reading frame of ppGaNTase-T3, flanked by 222 nt of 5'UTR and 754 nucleotides of 3'UTR. The aligned nt sequence of mouse and human ppGaNTase-T3 and the deduced amino acid sequences are shown in Fig. 1. The sequence

GGCACGAGGGCCACCCGAGTCGCCGGCGTCGC AGGADACCCTTTTACCGGCAAACCTATGCTAAAGAGTATAAGTAAACAAGGAAACCAAACGGTTATCTGTCAAGTAACAAGCATTTAATGACAGGAACAGA hT3 and get eac eta aag ega eta gta aaa eta eac att aaa aga eat tac eat aaa aag ete egg eag ett get I Met Ala His Leu Lys Arg Leu Val Lys Leu His Ile Lys Arg His Tyr His Arg Lys Phe Trp Lys <u>Leu Gly</u> GCA GTA ATT TTT TTC TTT ATA ATA GTT TTG GTT TTA ATG CAA AGA GAA GTA AGT GTT CAA TAT TCC AAA GAG ATT AAG GAT GCC ATG CCA AAA ATG CAA ATA GGA GCA CCT GTC AGG CAA AAC ATT GAT GCT GGT GAG AGA CCT 217 ATT AAA GAT GCA ATG CCA AAG ATG CAA ATA GGA GCG CCC ATT AAG GAG AAT ATC GAC GTC CGC GAG AGA CCC 73 Ile Lys Asp Ala Met Pro Lys Met Gln Ile Gly Ala Pro Ile Lys Glu Asn Ile Asp Val Arg Glu Arg Pro TGT TTG CAA GGA TAT TAT ACA GCA GCA GAA TTG AAG CCT GTC CTT GAC CGT CCA CCT CAG GAT TCA AAT GCA 97 Cys Leu Gln Gly Tyr Tyr Thr Ala Ala Glu Leu Lys Pro Val Phe Asp Arg Pro Pro Gln Asp Ser Asn Ala CCT GGT GCT TCT GGT AAA GCA TTC AAG ACA ACC AAT TTA AGT GTT GAA GAG CAA AAG GAA AAG GAA CGT GGG 121 Pro Gly Ala Ser Gly Lys Pro Phe Lys Ile Thr His Leu Ser Pro Glu Glu Glu Lys Glu Lys Glu Arg Gly GAA GOT AAA CAC TGC TTT AAT GCT TTC GCA AGT GAC AGG ATT TCT TTG CAC CGA GAT CTT GGA CCA GAC ACT 145 Glu Thr Lys His Cys Phe Asn Ala Phe Ala Ser Asp Arg Ile Ser Leu His Arg Asp Leu Gly Pro Asp Thr 169 Arg Pro Pro Glu Cys Ile Glu Gln Lys Phe Lys Arg Cys Pro Pro Leu Pro Thr Thr Ser Val Ile Ile Val TTT CAT AAT GAA GCG TGG TCC ACG TTG CTT AGA ACT GTC CAC AGT GTG CTC TAT TCT TCA CCT GCA ATA CTG CTG AAG GAA ATC ATT TTG GTG GAT GAT GCT AGT GTA GAT GAG TAC TTA CAT GAT AAA CTA GAT GAA TAT GTA 217 Leu Lys Glu Ile Ile Leu Val Asp Asp Ala Ser Val Asp Asp Tyr Leu His Glu Lys Leu Glu Tyr Ile AAA CAA TTT TCT ATA GTA AAA ATA GTC AGA CAA AGA GAA AGA AAA GGT CTG ATC ACT GCT CGG TTG CTA GGA 241 Lys Gln Phe Ser Ile Val Lys Ile Val Arg Gln Gln Glu Arg Lys Gly Leu Ile Thr Ala Arg Leu Leu Gly CCT CTG TTG GCC AGA ATA GCT GAG AAC TAC ACG GCT GTC GTA AGT CCA GAT ATT GCA TCC ATA GAT CTG AAC 289 Pro Leu Leu Ala Arg Ile Ala Glu Asn Tyr Thr Ala Val Val Ser Pro Asp Ile Ala Ser Ile Asp Leu Asn ACG TTT GAA TTC AAC AAA CCT TCT CCT TAT GGA AGT AAC CAT AAC CGT GGA AAT TTT GAC TGG AGT CTT TCA 313 Thr Phe Glu Phe Asn Lys Pro Ser Pro Tyr Gly Ser Asn His Asn Arg Gly Asn Phe Asp Trp Ser Leu Ser TTT GGC TGG GAG TCG CTT CCT GAT CAT GAG AAG CAA AGA AGG AAA GAT GAA ACC TAC CCA ATT AAA ACA CCC 337 Phe Gly Trp Glu Ser Leu Pro Asp His Glu Lys Gln Arg Arg Lys Asp Glu Thr Tyr Pro Ile Lys Thr Pro

```
GAA ATC TGG GGA GGT GAA AAT ATA GAA ATG TCT TTC AGA GTA TGG CAA TGT GGT GGG CAG TTG GAG ATT ATG
385 Glu Ile Trp Gly Gly Glu Asn Ile Glu Met Ser Phe Arg Val Trp Gln Cys Gly Gly Gln Leu Glu Ile Met
   CCT TGC TCT GTT GTT GGA CAT GTT TTT CGC AGC AAA AGC CCT CAT AGC TTT CCA AAA GGC ACT CAG GTG ATT
409 Pro Cys Ser Val Val Gly His Val Phe Arg Ser Lys Ser Pro His Thr Phe Pro Lys Gly Thr Gln Val Ile
    GCT AGA AAC CAA GTT CGC CTT GCA GAA GTC TGG ATG GAT GAA TAC AAG GAA ATA TTT TAT AGG AGA AAT ACA
GAT GCA GCA AAA ATT GTT AAA CAA AAA GCA TIT GGT GAT CTT TCA AAA AGA TTT GAA ATA AAA CAC CGT CTT
457 Asp Ala Ala Lys Ile Val Lys Gln Lys Ser Phe Gly Asp Leu Ser Lys Arg Phe Glu Ile Lys Lys Arg Leu
   CGG TGT AAA AAT TTT ACA TGG TAT CTG AAC AAC ATT TAT CCA GAG GTG TAT GTG CCA GAC CTT AAT CCT GTT
481 Gln Cys Lys Asn Phe Thr Trp Tyr Leu Asn Thr Ile Tyr Pro Glu Ala Tyr Val Pro Asp Leu Asn Pro Val
   ATA TCT GGA TAC ATT AAA AGC GTT GGT CAG CCT CTA TGT CTG GAT GTT GGA GAA AAC AAT CAA GGA GGC AAA
505 Ile Ser Gly Tyr Ile Lys Ser Val Gly Gln Pro Leu Cys Leu Asp Val Gly Glu Asn Asn Gln Gly Gly Lys
   CCA TTA ATT ATG TAT ACA TGT CAT GGA CTT GGG GGA AAC CAG TAC TTT GAA TAC TCT GCT CAA CAT GAA ATT
                    311-11
                               111 311 11
                                       311 131 11 31 11 331 111 33
1585 CCA TTG ATT CTG TAC ACG TGC CAC GGC CTC GGG GGA AAT CAG TAC TTC GAG TAT TCT GCT CAG CGT GAA ATC
529 Pro Leu Ile Leu Tyr Thr Cys His Gly Leu Gly Gly Asn Gln Tyr Phe Glu Tyr Ser Ala Gln Arg Glu Ile
   CGG CAC AAC ATC CAG AAG GAA TTA TGT CTT CAT GCT GCT CAA GGT CTC GTT CAG CTG AAG GCA TGT ACC TAC
           111 111 111 111
                                          111
1657 CGG CAC AAC ATC CAG AAG GAG CTG TGT CTT CAT GCT ACT CAG GGT GTC CAG CTG AAG GCA TGT GTC TAT
553 Arg His Asn Ile Gln Lys Glu Leu Cys Leu His Ala Thr Gln Gly Val Val Gln Leu Lys Ala Cys Val Tyr
   AAA GGT CAC AAG ACA GTT GTC ACT GGA GAG CAG ATA TGG GAG ATC CAG AAG GAT CAA CTT CTA TAC AAT CCA
577 Lys Gly His Arg Thr Ile Ala Pro Gly Glu Gln Ile Trp Glu Ile Arg Lys Asp Gln Leu Lyr Asn Pro
   TTC TTA AAA ATG TGC CTT TCA GCA AAT GGA GAG CAT CCA AGT TTA GTG TCA TGC AAC CCA TCA GAT CCA CTC
601 Leu Phe Lys Met Cys Leu Ser Ser Asn Gly Glu His Pro Asn Leu Val Pro Cys Asp Ala Thr Asp Leu Leu
   CAA AAA TGG ATA CTT AGC CAA AAT GAT TAA
              11 111 111 111 111 11
   TH 10 10 H
1873 CAA AAA TGG ATT TTT AGC CAA AAT GAA TAA GTGTTCCTTAAAATTAAGGAGTTGAAAAGGACATACTCTTCCTCATAAAACTGTG
625 Gln Lvs Trp Ile Phe Ser Gln Asn Glu
   ATGTTTTACAGTGTGAAGAAAATAATTTCCTTAGTAAAGTGAGGTGTGGTTGTACACTTGGGATCTACACACCTGCATCCACACTCACAGCTG
   AAAATGTTTTCCCTAATTTTAGGGGCAATAGAAAAAGATTTGATACTGTATTTTTATAACTATATAGAAATGGATCAATGAAGGCCAGTCATTTG
```

TOTMORACCOCTICAGAGACACCICIGGGGTTICTICTICTICTICAGAAGACCACCIAACTICAGATICCAGATICCAGATICCAGATICCAGATICCAGATICCAGATICCAGATICCAGATICCAGATICCAGATICCAGATICCAGATICCAGATICCAGATICCAGATICCAGATICAGAGGAGATICAGACCAGCTCAGACCACCACCACCACCAGCCAGCAGCAGCATICAGA

FIG. 1. Nucleotide and deduced amino acid sequences of mouse ppGaNTase-T3. The nucleotide sequence of mouse T3 is shown with corresponding nucleotide numbers on the left. The human T3 nucleotide sequence recently reported by Bennett et al (5) is shown above the mouse T3 sequence and homologous nucleotide sequences between human and mouse T3 are depicted by vertical lines. The deduced amino acid sequence of mouse T3 is also shown (italicized numbers on the left), where the potential N-glycosylation residues are denoted in bold and the purported membrane spanning region is underlined.

similarity of mouse ppGaNTase-T3 with other known isoforms of the transferase is shown in Table 2.

The message begins with a 222 nt 5' UTR that contains 3 termination codons, which are in frame with the AUG codon at position 223 (+1 in Fig. 1). A putative translation initiation site at position 223 agrees with the Kozak consensus sequence for eukaryotic translation

Mouse T1<sup>b</sup>

C. elegans (ZK688)<sup>a</sup>

%

65

47

Comparison of Mouse ppGaN1ase-13 with Other ppGaN1ases					
Isoform	Nucleotide Identity, %	AA Similarity,			
Human T1 <sup>a</sup>	51	64			
Human T2	49	59			
Human T3	87	96			


TABLE 2
Comparison of Mouse ppGaNTase-T3 with Other ppGaNTases

62

40

initiation in 6 out of 9 nt (14). The deduced amino acid sequence of mouse ppGaNTase-T3 reveals a type II membrane protein of 633 aa residues, with a predicted membrane spanning region of 15 aa residues and a cytoplasmic tail of 22 aa residues.

A single transcript of 3.2 Kb encoding ppGaNTase-T3 was detected by northern blot analysis of RNAs derived from a number of mouse tissues (Fig. 2A). The transcript was highly prevalent in the reproductive tract, principally in the testis and uterus, and to a lesser degree in the cervix with only trace levels detected in the ovary. ppGaNTase-T3 message was also highly abundant in sublingual gland, stomach and colon, with more moderate amounts present in the submandibular and parotid gland as well as the kidney. After surveying an extensive panel of



**FIG. 2.** Northern analysis of T3 expression in mouse tissues. Total RNA (from Balb/C mice) was extracted from the glands and organs listed above panel A. After electrophoresis on 1% formaldehyde-agarose gel and transfer to Hybond-N membranes, RNA was hybridized with a T3 specific probe (Pane A) and an 18s anti-rRNA probe (Panel B) as a control for RNA integrity. Each lane contains 15  $\mu$ g of total RNA. Size markers are indicated on the left.

<sup>&</sup>lt;sup>a</sup> The GeneBank accession numbers for human T1, human T2, human T3, and *C. elegans* are X85018, X85019, X92689, and L16621, respectively.

<sup>&</sup>lt;sup>b</sup> Mouse T1 sequence, F. K. Hagen and L. A. Tabak, unpublished.




FIG. 3. Occupancy of O-glycosylated residues on peptides EA2 and MCP2. The left-hand panels show differences in occupancy of residues on the substrate EA2 generated by ppGaNTase-T3 (upper left panel) and ppGaNTase-T1 (lower left panel). The right-hand panels illustrate differences in occupancy of residues on the peptide MCP2 generated by ppGaNTase-T3 (upper right panel) and ppGaNTase-T1 (lower right panel). The most highly glycosylated residue in each column was set to 1.0. Actual occupancies of residues were as follows: For the T1 isoform, Thr2 of EA2 had an occupancy of 30% and Ser12 of MCP2 had an occupancy of 39%. For the T3 isoform, Thr11 of EA2 had an occupancy of 10% and Ser1 of MCP2 had an occupancy of 47%.

mouse tissues, we find that ppGaNTase-T3 message is more widely expressed than suggested by the work of Bennett et al. (5). However, this result may be due to species-specific differences in expression between mouse and human.

ppGaNTase activity was detected in the culture supernatants of COS7 cells transfected with the mouse homologue of hEST T11328, verifying that this cDNA encodes a ppGaNTase. Peptide sequences derived from Muc 1 (Muc 1a and 1b), human intestinal (Muc 2) and rat salivary (EA 2) mucins were each glycosylated by recombinant ppGaNTase-T1 and ppGaNTase-T3 in vitro (Table 1), suggesting that one or both of these forms could play a role in the biosynthesis of these mucins. Similarly, several peptides based on membrane cofactor protein (MCP), a protein thought to play a role in reproductive functions in both the male and female reproductive tracts (11), were also glycosylated by both isoforms of transferase in vitro. In contrast, the peptide derived from testis associated spermadhesin protein (AWN) (10) was not glycosylated by either isoform of ppGaNTase (Table 1); perhaps this domain must be presented within a larger context of the spermadhesin molecule, or, alternatively, another isoform of ppGaNTase may be required to modify these sites.

The percent of each hydroxyamino acid occupied by GalNAc in O-glycosylated EA 2 and MCP 2 is summarized in Fig. 3. There are clear differences when each substrate is glycosylated with the two isoforms in vitro. We speculate that these differences suggest that multiple forms of ppGaNTase are required to optimally O-glycosylate multi-site substrates in vivo, as has been suggested for O-mannosylation in *S. cerevisiae* (15).

#### **ACKNOWLEDGMENTS**

This work was supported in part by NIH grant DE-08108. J.Z. was supported by T32 DE07202. The nucleotide sequences reported in this paper have been submitted to the GenBank with accession number U70538. We thank Pat Noonan for her help in preparing this manuscript.

#### REFERENCES

- Homa, F. L., Hollander, T., Lehman, D. J., Thomsen, D. R., and Elhammer, Å. P. (1993) J. Biol. Chem. 268, 12609–12616.
- 2. Hagen, F. K., VanWuyckhuyse, B. C., and Tabak, L. A. (1993) J. Biol. Chem. 268, 18960-18965.
- 3. Hagen, F. K., Gregoire, C. A., and Tabak, L. A. (1995) Glycoconj. J. 12, 901-909.
- Sørensen, T., White, T., Wandall, H. H., Kristensen, A. K., Roepstorff, P., and Clausen, H. (1995) J. Biol. Chem. 270, 24166–24173.
- 5. Bennett, E. P., Hassan, H., and Clausen, H. (1996) J. Biol. Chem. 271, 17006-17012.
- Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
- 7. Gendler, S. J., Lancaster, C. A., Taylor-Papadimitriou, J., Duhig, T., Peat, N., Burchell, J., Pemberton, L., Lalani, E.-N., and Wilson, D. (1990) *J. Biol. Chem.* **265**, 15286–15293.
- 8. Gum, J. R., Jr., Hicks, J. W., Toribara, N. W., Siddiki, B., and Kim, Y. S. (1994) J. Biol. Chem. 269, 2440-2446.
- 9. Albone, E. F., Hagen, F. K., VanWuyckhuyse, B. C., and Tabak, L. A. (1994) J. Biol. Chem. 269, 16845-16852.
- Sanz, L., Calvete, J. J., Mann, K., Schafer, W., Schmid, E. R., Amselgruber, W., Sinowatz, F., Ehrhard, M., and Topfer-Petersen, E. (1992) FEBS Lett. 300, 213–218.
- 11. Liszewski, M. K., Post, T. W., and Atkinson, J. P. (1991) Annu. Rev. Immunol. 9, 431-455.
- 12. O'Connell, B. C., Hagen, F. K., and Tabak, L. A. (1992) J. Biol. Chem. 267, 25010-25018.
- 13. Lowry, O. H., Rosebrough, N. J., Farr, A. L., and Randall, R. J. (1951) J. Biol. Chem. 193, 265-275.
- 14. Kozak, M. (1984) Nuc. Acids. Res. 12, 857-873.
- 15. Gentzsch, M., Immervoll, T., and Tanner, W., (1995) FEBS Lett. 377, 128-130.